


How alternatives to animal models can shape the future of biomedical research and medicine

3d.FAB Days à Lyon
9 et 10 juillet 2024

3D.FAB days
9-10th July 2024



PRO ANIMA SCIENTIFIC COMMITTEE: MULTI-LEVEL ACTIONS



RAISE AWARENESS



CITIZENS, SCIENTISTS, REGULATORS,
POLITICAL AND ECONOMIC ACTORS

FINANCE



NON-ANIMAL RESEARCH WITH
THE DESCROIX-VERNIER
ETHICS SCIENCE PRIZE



PUBLISH



SCIENCE, ISSUES, HEALTH
The only French journal
dedicated to non-animal
research

DIALOGUE




KEY PLAYERS IN THE SECTOR
Industrial researchers, regulators



BIOMEDICAL RESEARCH AND PHARMA: LIMITED BY OBSOLETE MODELS?



Drug development




Results that are not easily transposable and reproducible

Overall attrition rate of 95%



Sources: circabc.europa.eu & enseignementsup-recherche.gouv.fr



Basic Research
(~40%)



Applied Research
(~30%)




Regulatory and
Toxicology (<30%)



Clinical Trial


10 to 12 years for a drug to be approved (~\$2.6 billion)

Translational proportions since the first published animal study



Source: Ineichen BV, et al., *PLoS Biol* (2024)

BIOMEDICAL RESEARCH AND MEDICINE: LIMITED BY OBSOLETE MODELS?



(Xeno)Transplantation



Worldwide shortage of organs for transplantation



Clinical xenotransplantation has been a goal for more than a century



The reason

- Anatomically similar organs
- Advances in immunology and gene editing

Heart valves from pigs and cows are routinely grafted into patients



Failure and risks

- Immune rejection
- Immunosuppressive drugs leading to death
- Zoonoses
- Waste of resources and a disservice to patients

Surgeries involving pigs organs had resulted in failure

3D BIOPRINTING: A POTENTIAL REVOLUTION FOR RESEARCH AND PERSONALIZED MEDICINE



Organ transplantation

- Overcoming the shortage
- Reducing the cases of rejection
- Overcoming Gender Differences
- Enhancing the survival of patients
- More ethical and promising than xenotransplantation

Tissue regeneration

- Removal of congenital defects
- Regenerate tissue for hearts, corneas, and other
- Personalised implants

Medical devices


- Training and education
- Facilitate surgery
- Educate patients

Understanding of disease

- Disease/tumour models
- Organ-on-chip models (tissue and material / scaffold)
- Reducing gender, age and other genetic biases

Drug development


- Toxicity testing / metabolism studies
- Target identification and validation
- Prioritization of lead candidates
- Personalized medicine




Sources:

. *Imagining futures of 3D bioprinting*. World Health Organization; 2023
Shopova D, et al. *Bioengineering* (2023)


NON-ANIMAL METHODS: IN VITRO, IN SILICO, EX VIVO...




3D organoids




OoC



Single-cell
Multi-omics



Advanced
imaging



AI, Machine
Learning



3D-printed
organs


Combinatorial effect

**Better predictivity, efficiency, and
reproducibility**

Saving time and money

Benefit for patients

3D BIOPRINTING & NAMS: CHALLENGES AND OPPORTUNITIES



The aim

- identify present **actions** to ensure
- future availability of **safe, effective** applications
- **equitable distribution** of its benefits.
- identify any **risks or dual-use issues**

Imagining futures of 3D bioprinting. World Health Organization; 2023

• DESCROIX-VERNIER ETHICSCIENCE PRIZE 2025

APPLICATION OPEN

Deadline August 30, 2024

PRIX
DESCROIX-VERNIER
ETHICSCIENCE
LA SCIENCE A UNE ÂME

• NAMS NETWORK

A LINKEDIN GROUP


<260 members
different sectors and
countries



• WEEKLY NEWSLETTER ON NAMS

*For researchers/scientists, citizens, media, public
authorities, economic actors*

SUBSCRIBE





THANK YOU
FOR YOUR ATTENTION

 lilas@proanima.fr


 www.proanima.fr



THE DESCROIX-VERNIER ETHICSCIENCE PRIZE 2025



Categories



Innovation 50k€ - aims to acknowledge disrupting, innovative and/or high risk research tool or discovery ; open to any research field (biomedical and toxicology)



Development & Applicability 50k€ - focus on existing data and tools integration (i.e., method that integrates available toxicology tests with epidemiology, that can be applied for human health) ; open to any research field (biomedical and toxicology)



Forward-Looking Project 10k€ - aims to encourage a young outstanding and promising researcher with regard to the exceptional quality of his/her work and engagement



APPLICATION OPEN




Deadline August 30, 2024

Awards ceremony in March 2025

3D BIOPRINTING: A POTENTIAL A REVOLUTION FOR RESEARCH AND PERSONALIZED MEDICINE



3D bioprinting annual publications from 2007 to 2022



Source: Ding, Zhiyu et al. *Frontiers in bioeng and biotech* (2023)

Precise, controlled, reproducible

Bio-available, patient-derived

More ethical and affordable

Complex, vascularized

NON-ANIMAL METHODS (NAMs): GAINING INTERNATIONAL MOMENTUM

FDA Modernisation Act 2.0

US



NAMs can be used to instead of animal studies for drug development.

Roadmap

European Commission



Replacing the use of animals in next-generation chemical risk assessment.

Transition centre

The Netherland



Dutch National Growth Fund invests 124,5 million in transition to animal-free innovation


“ The Netherlands is setting the stage for transition science, but The Netherlands cannot achieve the change alone, as regulations usually work on a global scale.

Prof. Merel Ritskes-Hoitinga ”

NAMS NETWORK

Tools


A LinkedIn group



<260 members

Different sectors

27 countries



WEEKLY NEWSLETTER ON NAMS

Researchers/scientists, citizens, media, public authorities, economic actors



COMITÉ SCIENTIFIQUE PRO ANIMA

NEWSLETTER NAMS

**L'ACTUALITÉ DES MÉTHODES NON-ANIMALES
EN EUROPE ET DANS LE MONDE**

Réglementation, nominations, partenariats, avancées de la recherche biomédicale, tests toxicologiques...

SUBSCRIBE

